These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 25434284

  • 1. The potential of class 3 semaphorins as both targets and therapeutics in cancer.
    Mishra R, Kumar D, Tomar D, Chakraborty G, Kumar S, Kundu GC.
    Expert Opin Ther Targets; 2015 Mar; 19(3):427-42. PubMed ID: 25434284
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Semaphorins in cancer.
    Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O.
    Front Biosci; 2005 Jan 01; 10():751-60. PubMed ID: 15569615
    [Abstract] [Full Text] [Related]

  • 5. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.
    Kigel B, Varshavsky A, Kessler O, Neufeld G.
    PLoS One; 2008 Sep 26; 3(9):e3287. PubMed ID: 18818766
    [Abstract] [Full Text] [Related]

  • 6. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer.
    Mastrantonio R, You H, Tamagnone L.
    Theranostics; 2021 Sep 26; 11(7):3262-3277. PubMed ID: 33537086
    [Abstract] [Full Text] [Related]

  • 7. Semaphorin signaling in vascular and tumor biology.
    Neufeld G, Lange T, Varshavsky A, Kessler O.
    Adv Exp Med Biol; 2007 Sep 26; 600():118-31. PubMed ID: 17607951
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Semaphorins in angiogenesis and tumor progression.
    Neufeld G, Sabag AD, Rabinovicz N, Kessler O.
    Cold Spring Harb Perspect Med; 2012 Jan 26; 2(1):a006718. PubMed ID: 22315716
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression patterns and pathogenesis of Semaphorin class 4 subfamily proteins in solid tumors.
    Jiang D, Chen X, Li X, Qiu J, Xu P, Li X.
    Neoplasma; 2024 Feb 26; 71(1):1-12. PubMed ID: 38295103
    [Abstract] [Full Text] [Related]

  • 14. Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression.
    Toledano S, Nir-Zvi I, Engelman R, Kessler O, Neufeld G.
    Int J Mol Sci; 2019 Jan 28; 20(3):. PubMed ID: 30696103
    [Abstract] [Full Text] [Related]

  • 15. Relation of immune semaphorin/plexin signaling to carcinogenesis.
    Műzes G, Sipos F.
    Eur J Cancer Prev; 2014 Sep 28; 23(5):469-76. PubMed ID: 24922268
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Semaphorin signaling in bone.
    Verlinden L, Vanderschueren D, Verstuyf A.
    Mol Cell Endocrinol; 2016 Sep 05; 432():66-74. PubMed ID: 26365296
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Semaphorins and tumor angiogenesis.
    Serini G, Maione F, Giraudo E, Bussolino F.
    Angiogenesis; 2009 Sep 05; 12(2):187-93. PubMed ID: 19266292
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.